(NYSE: CTLT) Catalent's forecast annual revenue growth rate of 9.77% is forecast to beat the US Drug Manufacturers - Specialty & Generic industry's average forecast revenue growth rate of 8.76%, and and it is also forecast to beat the US market's average forecast revenue growth rate of 9.2%.
Catalent's revenue in 2023 is $4,825,000,000.On average, 6 Wall Street analysts forecast CTLT's revenue for 2023 to be $949,741,824,188, with the lowest CTLT revenue forecast at $937,610,298,690, and the highest CTLT revenue forecast at $965,090,738,730. On average, 4 Wall Street analysts forecast CTLT's revenue for 2024 to be $1,039,413,901,351, with the lowest CTLT revenue forecast at $1,012,295,188,125, and the highest CTLT revenue forecast at $1,060,741,386,284.
In 2025, CTLT is forecast to generate $1,165,084,275,186 in revenue, with the lowest revenue forecast at $1,165,084,275,186 and the highest revenue forecast at $1,165,084,275,186.